Johnson and Johnson-Product Pipeline Review-2015

Johnson and Johnson-Product Pipeline Review-2015

  • Products Id :- GMDHC06949CDB
  • |
  • Pages: 326
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Johnson & Johnson-Product Pipeline Review-2015


Global Markets Direct's, 'Johnson & Johnson-Product Pipeline Review-2015', provides an overview of the Johnson & Johnson's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Johnson & Johnson's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Johnson & Johnson including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Johnson & Johnson's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Johnson & Johnson's pipeline products

Reasons To Buy

Evaluate Johnson & Johnson's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Johnson & Johnson in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Johnson & Johnson's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Johnson & Johnson and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Johnson & Johnson

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Johnson & Johnson and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Johnson & Johnson Snapshot 7

Johnson & Johnson Overview 7

Key Information 7

Key Facts 7

Johnson & Johnson-Research and Development Overview 8

Key Therapeutic Areas 8

Johnson & Johnson-Pipeline Review 17

Pipeline Products by Stage of Development 17

Pipeline Products-Monotherapy 18

Pipeline Products-Combination Treatment Modalities 19

Pipeline Products-Partnered Products 20

Pipeline Products-Out-Licensed Products 23

Johnson & Johnson-Pipeline Products Glance 25

Johnson & Johnson-Late Stage Pipeline Products 25

Johnson & Johnson-Clinical Stage Pipeline Products 28

Johnson & Johnson-Early Stage Pipeline Products 32

Johnson & Johnson-Unknown Stage Pipeline Products 36

Johnson & Johnson-Drug Profiles 37

abiraterone acetate 37

bedaquiline fumarate 40

golimumab 43

trabectedin 46

ustekinumab 51

bortezomib 54

rivaroxaban 59

(canagliflozin + metformin hydrochloride XR) 64

(darunavir + cobicistat + emtricitabine + tenofovir alafenamide) 65

(sumatriptan succinate + naproxen sodium) 67

canagliflozin 69

daratumumab 71

fulranumab 74

guselkumab 77

infliximab 80

JNJ-56021927 82

sirukumab 84

tapentadol hydrochloride 87

ALS-8176 89

CNTO-3157 90

CNTO-6785 91

esketamine hydrochloride 93

Gene Therapy for HIV-1 Infection 95

imetelstat sodium 96

JNJ-40346527 98

JNJ-40411813 99

JNJ-42039556 100

JNJ-42756493 102

JNJ-49095397 104

JNJ-53718678 106

JNJ-54861911 107

JNJ-56914845 109

ORM-12741 111

quisinostat 112

rilpivirine 114

siltuximab 116

Small Molecule for Smoking Cessation 119

Small Molecule to Inhibit Beta Secretase for Alzheimer's Disease 120

tipifarnib 121

TMC-310911 123

toreforant 124

VX-787 126

CNTO-2476 127

telaprevir 128

Vaccine for Prostate Cancer 132

AL-335 135

CNTO-0007 136

CNTO-7160 137

CSL-362 138

EVT-100 Series 139

EVT-103 140

JNJ-38877618 142

JNJ-42165279 143

JNJ-42721458 144

JNJ-42847922 145

JNJ-43260295 146

JNJ-47910382 147

JNJ-49122944 148

RV-1162 149

RV-1729 150

ALS-8112 151

Small Molecules for Rhinovirus Infections 152

Small Molecules to Inhibit RNA-Dependent RNA Polymerase for Influenza 153

Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections 154

ADU-214 155

ADU-741 156

AL-516 157

AV-368 158

CNTO-530 159

flubendazole 160

Gene Therapy for Arteriosclerosis and Endothelial Dysfunction 161

JNJ-26070109 162

JNJ-26993135 163

JNJ-28307474 164

JNJ-28312141 165

JNJ-28610244 166

JNJ-31020028 167

JNJ-35815208 168

JNJ-39933673 169

JNJ-40279486 170

JNJ-40413269 171

JNJ-41477670 172

JNJ-42314415 173

JNJ-47965567 174

JNJ-5234801 175

mAb-1A11 176

mAb-5G7 177

MGD-011 178

Monoclonal Antibody for Autoimmune Diseases 179

Monoclonal Antibody to Target VISTA for Cancer 180

Nucleozin 181

Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases 182

Recombinant Proteins for Rheumatoid Arthritis and Asthma 183

RV-1088 184

S-961 185

Small Molecule 1 for Type 2 Diabetes 186

Small Molecule 2 for Type 2 Diabetes 187

Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia 188

Small Molecule to Inhibit FLT3 for AML 189

Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity 190

Small Molecules to Inhibit FMS for Rheumatoid Arthritis 191

Stem Cell Therapy for Diabetes 192

VE-202 193

ALS-2135 194

Cell Therapy for Cancer 195

DiTU 196

Drugs for Cancer 197

ESN-JJ 198

influenza vaccine 199

JNJ-39729209 200

LCTA-949 201

Peptides to Inhibit Ion Channel for Chronic Pain 202

Small Molecules for Central Nervous System Disorders 203

Small Molecules for Hepatitis B 204

Small Molecules for Lymphoma 205

Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer 206

Small Molecules to Antagonize CCR2 for Type II Diabetes 207

Small Molecules to Block Cav2.2 Channel for Chronic Pain 208

Small Molecules to Inhibit Kinase for Uveitis and Inflammatory Bowel Disease 209

TMC-207 Back Up 210

VX-353 211

Drugs for Prostate Cancer 212

Johnson & Johnson-Pipeline Analysis 213

Johnson & Johnson-Pipeline Products by Target 213

Johnson & Johnson-Pipeline Products by Route of Administration 219

Johnson & Johnson-Pipeline Products by Molecule Type 220

Johnson & Johnson-Pipeline Products by Mechanism of Action 221

Johnson & Johnson-Recent Pipeline Updates 226

Johnson & Johnson-Dormant Projects 287

Johnson & Johnson-Discontinued Pipeline Products 291

Discontinued Pipeline Product Profiles 291

Johnson & Johnson-Company Statement 294

Johnson & Johnson-Locations And Subsidiaries 296

Head Office 296

Other Locations & Subsidiaries 296

Appendix 316

Methodology 316

Coverage 316

Secondary Research 316

Primary Research 316

Expert Panel Validation 316

Contact Us 316

Disclaimer 317

List of Tables

Johnson & Johnson, Key Information 16

Johnson & Johnson, Key Facts 16

Johnson & Johnson-Pipeline by Indication, 2015 18

Johnson & Johnson-Pipeline by Stage of Development, 2015 26

Johnson & Johnson-Monotherapy Products in Pipeline, 2015 27

Johnson & Johnson-Combination Treatment Modalities in Pipeline, 2015 28

Johnson & Johnson-Partnered Products in Pipeline, 2015 29

Johnson & Johnson-Partnered Products/ Combination Treatment Modalities, 2015 30

Johnson & Johnson-Out-Licensed Products in Pipeline, 2015 32

Johnson & Johnson-Out-Licensed Products/ Combination Treatment Modalities, 2015 33

Johnson & Johnson-Pre-Registration, 2015 34

Johnson & Johnson-Filing rejected/Withdrawn, 2015 35

Johnson & Johnson-Phase III, 2015 36

Johnson & Johnson-Phase II, 2015 37

Johnson & Johnson-Phase I, 2015 39

Johnson & Johnson-IND/CTA Filed, 2015 41

Johnson & Johnson-Preclinical, 2015 42

Johnson & Johnson-Discovery, 2015 44

Johnson & Johnson-Unknown, 2015 45

Johnson & Johnson-Pipeline by Target, 2015 223

Johnson & Johnson-Pipeline by Route of Administration, 2015 228

Johnson & Johnson-Pipeline by Molecule Type, 2015 229

Johnson & Johnson-Pipeline Products by Mechanism of Action, 2015 231

Johnson & Johnson-Recent Pipeline Updates, 2015 235

Johnson & Johnson-Dormant Developmental Projects,2015 296

Johnson & Johnson-Discontinued Pipeline Products, 2015 300

Johnson & Johnson, Subsidiaries 305

List of Figures

Johnson & Johnson-Pipeline by Top 10 Indication, 2015 18

Johnson & Johnson-Pipeline by Stage of Development, 2015 26

Johnson & Johnson-Monotherapy Products in Pipeline, 2015 27

Johnson & Johnson-Partnered Products in Pipeline, 2015 29

Johnson & Johnson-Out-Licensed Products in Pipeline, 2015 32

Johnson & Johnson-Pipeline by Top 10 Target, 2015 222

Johnson & Johnson-Pipeline by Top 10 Route of Administration, 2015 228

Johnson & Johnson-Pipeline by Top 10 Molecule Type, 2015 229

Johnson & Johnson-Pipeline Products by Top 10 Mechanism of Action, 2015 230

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Johnson & Johnson; Johnson & Johnson - Key Therapeutics; Johnson & Johnson - Pipeline Overview and Promising Molecules; Johnson & Johnson - News; Johnson & Johnson - Latest Updates; Johnson & Johnson - Pipeline; Johnson & Johnson - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 108615
Site License
USD 3000 INR 217230
Corporate User License
USD 4500 INR 325845



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]